A recap of business developments from life sciences companies around the world, including U.K.-based Vaccitech Limited and the University of Oxford touting positive safety and efficacy trends in a mid-stage prostate cancer study.

Harmony Biosciences snagged approval from the U.S. FDA for the company’s first commercial product, a treatment for narcolepsy.

Merck agreed to acquire Tilos, a privately held biopharma company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.

BioLineRx Ltd. announced the expansion of its immuno-oncology collaboration with Merck & Co. Inc. for the support of a Phase 2a program investigating BioLineRx’s BL-8040 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with metastatic pancreatic cancer.

Peptidream Inc. scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment of multiple disease targets.

Janssen Pharmaceuticals, a division of healthcare giant Johnson & Johnson, and Tokyo-based Peptidream will develop peptide-based therapies to target multiple metabolic and cardiovascular targets.

La Jolla Pharmaceutical Co.’s shares surged after the company said its drug to treat low blood pressure succeeded in a key trial.

January 27, 2016By Mark Terry, BioSpace.com Breaking News Staff   Menlo Park, Calif.-based Adicet Bio, Inc. announced today that it had closed on a $51 million Series A financing round. The financing was led by OrbiMed and joined by Novartis Venture Fund and Pontifax. In addition, Adicet announced it had acquired Israeli company Applied Immune […]

Research Triangle Park, N.C.-based Phoundry Pharmaceuticals, Inc. announced the completion of its first seed financing on Tuesday. The company raised $500,000, led by Pappas Ventures, and is planning a second tranche for another $500,000 in upcoming months, with hopes of moving to a Series A round.   The company was recently founded by six researchers […]